Eramet confirms its 2026 capital increase project, backed by the support of its reference shareholders and by a strategic investment by the French State

Not for release, publication or distribution, directly or indirectly, in or into the United States, Canada, Australia, Japan or South Africa.

Paris, 12th August 2026, 07:00 p.m.

PRESS RELEASE

Eramet confirms its 2026 capital increase project, backed by the support of its reference shareholders and by a strategic invest-
ment by the French State

• Confirmation of the intention to launch in Q4 2026 the €500 million capital increase with Prefer-
  ential Subscription Rights (“PSRs”) announced in February 2026
• A necessary transaction to restore the Group’s financial position, strengthen its equity base,
  maintain compliance with its bank covenants and continue executing its strategy. Eramet is also
  pursuing the other two pillars of its funding plan: performance improvement (in particular through
  ReSolution), and asset monetization.
• Agreement reached between the two reference shareholders on the terms of their participation
  in the rights issue
• Strategic decision by the French State to increase its stake in Eramet through a strategic invest-
  ment by the Agence des Participations de l’Etat (“APE”), in line with its objectives to secure
  critical metals. Accordingly, as part of the transaction:
  • The APE will subscribe for its pro-rata share (27.1% of the share capital) and purchase,
    depending on the transaction reference price, all or part of Sorame-CEIR’s PSRs so that
    APE’s effective voting rights¹ at a General Meeting do not exceed 49%;
  • Should the APE not purchase all of Sorame-CEIR’s PSRs, Sorame-CEIR would then sub-
    scribe to the balance of the PSRs it received; Sorame-CEIR would subsequently have the
    right to exercise a put option, while the APE would have the right to exercise a call option,
    over the new shares subscribed for by Sorame-CEIR in the rights issue.
• The Company’s other shareholders, in particular the free-float, will be able to participate in the
  rights issue by exercising their PSRs during the subscription period². Those who do not wish to
  participate may sell their PSRs on the market, notably allowing existing shareholders or new
  investors to acquire them and participate in the rights issue³.
• Following its investment, the APE will become the Group’s largest shareholder, confirming Era-
  met’s strategic importance to French and European sovereignty in critical metals. Sorame-CEIR
  will become the second-largest shareholder.
• Following its investment, APE will become the Group’s largest shareholder, underscoring Era-
  met’s strategic importance to French and European sovereignty in critical metals. Sorame-CEIR
  will become the Group’s second-largest shareholder.

Christel Bories, Chair and Chief Executive Officer of Eramet:

“This transaction, which is essential to secure the Group’s financial sustainability, marks a major
milestone for Eramet. It will enable us to execute in 2026 the capital increase announced in February
as part of our funding plan.

On behalf of the Board of Directors, I welcome the agreement reached by our two reference share-
holders in the Group’s best interests, as well as the French State’s strategic decision to increase its
equity stake in Eramet.

We are taking a decisive step towards strengthening our future, pursuing our strategic roadmap and
actively contributing to securing supplies of critical metals.”

Head office – 10, Boulevard de Grenelle – CS 63205 – 75015 Paris – www.eramet.com

Not for release, publication or distribution, directly or indirectly, in or into the United States, Canada, Australia, Japan
or South Africa.

Roland Lescure, Minister for the Economy, Finance and Industrial, Energy and Digital Sover-
eignty:

“This agreement demonstrates the Government’s commitment to strengthening France’s strategic
autonomy in the field of critical minerals and metals. Against a backdrop of intensifying international
competition and the need to secure supplies of critical metals, we are making an ambitious commit-
ment by becoming the Company’s largest shareholder.”

Jérôme Duval, representative of Sorame-CEIR:

“As an Eramet shareholder since 1999, Sorame-CEIR is today renewing its commitment alongside
the French State at a decisive moment.

By supporting this capital increase, we are opening, together with the French State, a new chapter
in the Group’s history, focused on critical metals. This renewed partnership will give Eramet the
means to establish itself as a key player in French and European sovereignty. Against a complex
geopolitical backdrop, the French State’s commitment will be more valuable than ever in supporting
the Group’s development. We are pursuing this shared ambition for Eramet, its employees and all
its shareholders.”

***

An analyst and investor call will be held on Monday, 12 October 2026 at 7:00 p.m. (Paris time). The
call will be webcast and conducted in English, hosted by Christel Bories, Chair and CEO, and Simon
Henochsberg, CFO. The webcast will be available on the Investors page of the Eramet website, at
www.eramet.com, where a replay will also be posted following the event.

***

At its meeting on 12 October 2026, the Board of Directors of Eramet approved the structuring of the
two reference shareholders’ subscription, which will be formalized in the coming days ahead of the
planned launch of the capital increase in Q4 2026.

Following the announcement of the capital increase in February 2026, several investors expressed
an interest in participating in the transaction. The Board of Directors assessed the various options in
light of the Company’s corporate interest and unanimously⁴ selected the solution arising from the
agreement between the reference shareholders. Beyond securing the execution of the transaction
and covering the Group’s immediate financing needs, this solution is aligned with France’s and Eu-
rope’s strategy to secure supplies of critical metals, while preserving Eramet’s ability to enter into
other partnerships at a later date.

⧫ Description of the transaction

Thanks to the agreement reached between the reference shareholders, the French State, through
APE⁵, will participate in the capital increase in two ways:

• Subscription for its pro rata share on an irreducible basis, corresponding to 27.1% of the
  share capital;
• Purchase at a 5% discount to their theoretical value and exercise of all or part of Sorame-
  CEIR’s PSRs, ensuring that the APE’s stake represents no more than 49% of the effective
  voting rights¹ at a General Meeting.

Should the APE not purchase all of Sorame-CEIR’s PSRs for the reason described above:

• Sorame-CEIR would reinvest to exercise up to its remaining PSRs and to subscribe for new
  shares in the capital increase;
• The APE would then have the option to purchase, and Sorame-CEIR the option to sell, the
  new shares subscribed for by Sorame-CEIR in the capital increase, under call and put op-
  tions. Both options would cover a number of shares such that the French State would not
  exceed 50% of the Company’s share capital. The exercise price per share would be close to
  the TERP⁶,⁷. The options would be entered into following receipt of the opinion of the em-
  ployee representative bodies.

Exercise of the options would also be subject to obtaining the required regulatory approvals
from the competent authorities.

As part of this agreement and the resulting changes in Eramet’s shareholder base, Sorame-CEIR
has agreed to convert its shares into bearer form upon completion of the transaction and to under-
take to hold (or use) no more than 30% of the Company’s effective¹ voting rights as from the date
on which the above regulatory approvals are obtained or, as the case may be, the exercise of one
of the aforementioned options.

The APE would thus become the Group’s largest shareholder and Sorame-CEIR its second-largest
shareholder. They would also enter into a new shareholders’ agreement.

In connection with the transaction, Eramet also undertakes not to resume dividend distributions until
its adjusted leverage⁸ falls back below 1.0x.

Given the proposed structure of the transaction, the French State will seek a waiver from the French
Financial Markets Authority (Autorité des Marchés Financiers, “AMF”) regarding the obligation to
launch a mandatory public offer resulting from individual threshold crossings triggered by its sub-
scription to the capital increase, as well as from the potential exercise of the call and put options and
the change in the shareholders’ concert arrangement. Obtention of such a final, non-appealable
waiver, will be a condition precedent to the subscription commitments that will underpin completion
of the capital increase.

This investment by the APE builds on the reference shareholders’ continued support for the Group’s
strategy and underscores the French State’s commitment to Eramet as a key company contributing
to sovereignty and securing access to critical metals.

⧫ Transaction background

The Group had stated that the capital increase, announced in February 2026 as part of its funding
plan, was essential to restore its financial position and avoid any risk of breaching its bank covenants.
As disclosed in its full-year results announcement, 2025 was a difficult year for Eramet, marked by
significant losses, an increase in net debt, adjusted leverage of 5.5x and gearing⁹ of 125%, resulting
in breaches of the Group’s bank covenants. While operating performance improved in H1 2026, the
Group also reiterated in its half-year communication the need to continue restoring its financial po-
sition in a sector highly exposed to metal price volatility.

The Company therefore intends to complete the transaction in Q4 2026. Failure to complete it by
mid-2027 would be detrimental to the Company’s financial position (in particular its ability to comply
with its bank covenants as of mid-2027), and would significantly complicate the necessary refinanc-
ing of debt maturing in the short term.

Thus, at a time when the Company’s financial sustainability had been called into question, this capital
increase will enable Eramet to strengthen its balance sheet and continue implementing the other
pillars of this plan, namely performance improvement and asset monetization, under the best possi-
ble conditions. The plan is intended to enable the Group to return to growth in the medium-term.

⧫ Transaction timetable

Eramet will begin preparatory work for the capital increase in the coming days. To this end, the Group
will gather a banking syndicate to assist with the preparation of the transaction documentation and
ensure the proper execution of the transaction.

The transaction is expected to be executed following the publication of Q3 turnover and before year-
end, subject to market conditions and the APE obtaining from the AMF a waiver from its obligation
to file a mandatory public offer, with such waiver being final and no longer subject to appeal.

Important information

No communication and no information in respect of the transaction referenced in this document may be distributed to the public in any juris-
diction where a registration or approval is required. No steps have been or will be taken in any jurisdiction (other than France) where such steps
would be required. The issue, the subscription for or the purchase of securities of Eramet S.A. (“Eramet” or the “Company”) may be subject
to specific legal or regulatory restrictions in certain jurisdictions. Eramet assumes no responsibility for any violation of any such restrictions by
any person.

This document is not and should not be construed as a “prospectus” within the meaning of Regulation (EU) 2017/1129 of the European Parlia-
ment and of the Council of 14 June 2017, as amended (the “EU Prospectus Regulation”) or within the meaning of the Public Offers and Ad-
missions to Trading Regulations 2024 (the “POATR”).

In accordance with the EU Prospectus Regulation, the Company will make available a French voluntary prospectus relating to the share capital
increase with preferential subscription rights (the “Rights Issue”) prepared in accordance with the EU Prospectus Regulation that will be sub-
mitted for the approval of the French financial markets authority (Autorité des marchés financiers) in connection with the public offering in
France (including New Caledonia (la Nouvelle-Calédonie)) and the admission on Euronext Paris of the new shares issued in the Rights Issue.

With respect to the member states of the European Economic Area other than France (the “Member States”), no action has been undertaken
or will be undertaken to make an offer to the public of securities requiring the publication of a prospectus in any Member States. As a result,
any securities of Eramet may only be offered in Member States (i) to “qualified investors”, as defined by the EU Prospectus Regulation; (ii) to
fewer than 150 natural or legal persons per Member State, other than “qualified investors” (as defined in the EU Prospectus Regulation); or (iii)
in any other circumstances, not requiring Eramet to publish a prospectus as provided under Article 1(4) of the EU Prospectus Regulation; and
provided that none of the offers mentioned in paragraphs (i) to (iii) above requires the publication of a prospectus by Eramet pursuant to Article
3 of the EU Prospectus Regulation, a supplement to the EU Prospectus Regulation pursuant to Article 23 of the EU Prospectus Regulation, or
the publication of an Annex IX document pursuant to Article 1(4) of the EU Prospectus Regulation.

With respect to the United Kingdom, no action has been undertaken or will be undertaken to make an offer to the public of securities requiring
the publication of a prospectus in the United Kingdom. As a result, any securities of Eramet may only be offered in the United Kingdom (i) to
“qualified investors”, as defined under paragraph 15 of Schedule 1 to the POATR; (ii) to fewer than 150 natural or legal persons, other than
“qualified investors” (as defined under paragraph 15 of Schedule 1 to the POATR); or (iii) in any other circumstances falling within Part 1 of
Schedule 1 to the POATR.

This document and any other materials in relation to the securities of Eramet have not been made, and have not been approved, by an “au-
thorised person” within the meaning of Section 21(1) of the Financial Services and Markets Act 2000 (as amended, the “FSMA”). As a conse-
quence, this document is directed only at persons who (A) are located outside the United Kingdom or (B) are “qualified investors” within the
meaning of paragraph 15 of Schedule 1 to the POATR (i) who are investment professionals falling within Article 19(5) of the Financial Services
and Markets Act 2000 (Financial Promotion) Order 2005 (as amended, the “Order”), (ii) who fall within Article 49(2)(a) to (d) of the Order, or (iii)
to whom it may be lawfully communicated (all such persons collectively being referred to as “Relevant Persons”). Any securities are intended
only for Relevant Persons and no invitation, offer or agreements to subscribe, purchase or acquire the securities may be proposed or made
other than with Relevant Persons. Any person other than a Relevant Person may not act or rely on this document or any provision thereof. This
document is not a prospectus which has been approved by the Financial Conduct Authority or any other United Kingdom regulatory authority
within the meaning of Section 85 of the FSMA.

This document does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States of
America, its territories and possessions, any State of the United States of America and the District of Columbia (the “United States”). Securi-
ties may not be offered, subscribed or sold in the United States absent registration under the U.S. Securities Act of 1933, as amended (the
“U.S. Securities Act”), except pursuant to an exemption from, or in a transaction not subject to, the registration requirements thereof. The
securities of Eramet have not been and will not be registered under the U.S. Securities Act. Eramet does not intend to register any portion of
the offering of its securities in the United States or to conduct a public offering of its securities in the United States.

The distribution of this document in certain countries may constitute a breach of applicable law. The information contained in this document
does not constitute an offer of securities for sale in the United States, Canada, Australia, Japan or South Africa.

This document may not be published, forwarded or distributed, directly or indirectly, in or into the United States, Canada, Australia, Japan or
South Africa.

Calendar

12.10.2026: Analyst and investor call (7:00 pm, Paris time)
29.10.2026: Publication of 2026 Group third-quarter turnover

Not for release, publication or distribution, directly or indirectly, in or into the United States, Canada, Australia, Japan
or South Africa.

ABOUT ERAMET

Eramet transforms the Earth’s mineral resources to provide sustainable and responsible solutions to the growth
of the industry and to the challenges of the energy transition.

Its employees are committed to this through their civic and contributory approach in all the countries where the
mining and metallurgical group is present.

Manganese, nickel, mineral sands and lithium: Eramet recovers and develops metals that are essential to the
construction of a more sustainable world.

As a privileged partner of its industrial clients, the Group contributes to making robust and resistant infrastruc-
tures and constructions, more efficient means of mobility, safer health tools and more efficient telecommuni-
cations devices.

Fully committed to the era of metals, Eramet’s ambition is to become a reference for the responsible transfor-
mation of the Earth’s mineral resources for living well together.

www.eramet.com

INVESTOR CONTACT

Director of Investor Relations
Sandrine Nourry-Dabi
T. +33 1 45 38 37 02
sandrine.nourrydabi@eramet.com

PRESS CONTACT

Group Communications Director
Laurent Cicolella
+33 1 45 38 41 38
laurent.cicolella@eramet.com

Media Relations Officer
Nedjma Amrani
T. +33 7 65 65 44 49
nedjma.amrani@eramet.com

Notes

1. Effective voting rights: voting rights exercisable at a General Meeting, calculated on the basis of the average quorum across the 2024 to 2026 General Meetings
2. For retail shareholders, as the transaction is an offer to the public open in France, eligibility to participate must be assessed on a case-by-case basis, depending on their country of residence and in accordance with applicable securities laws and regulations
3. Subject to applicable securities regulations outside France
4. Directors representing reference shareholders having abstained
5. Acting through FSI-Equation (Fonds Stratégique d’Investissement)
6. Theoretical Ex-Rights Price (TERP): the theoretical share price after detachment of the preferential subscription right
7. TERP less an amount equal to 5% of the product of (i) the theoretical value of one PSR and (ii) the number of PSRs required to sub-
   scribe for one new share
8. Adjusted leverage: as defined in the Group’s financial communications
9. Within the meaning of bank covenants